New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 27, 2014
05:49 EDTTEVASynthon says glatiramer shows equivalence to Teva's Copaxone
Synthon announced that the companyís glatiramer acetate met the main endpoint of a late-stage study in patients with relapsing remitting multiple sclerosis. The Phase III Glatiramer Acetate clinical trial to assess equivalence with Teva's (TEVA) Copaxone is to-date the only Phase III study conducted with a generic version of Copaxone and has demonstrated an equivalent efficacy and safety profile for Synthonís glatiramer acetate compared to Copaxone, Synthon said. Synthon has already submitted an Abbreviated New Drug Application for glatiramer acetate for injection in pre-filled syringes to the FDA in November 2011.
News For TEVA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 20, 2014
06:28 EDTTEVAAllergan price target raised to $210 from $190 at Citigroup
Subscribe for More Information
October 14, 2014
11:23 EDTTEVABIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information
11:19 EDTTEVATeva upgraded to Buy from Hold at Standpoint Research

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use